论文部分内容阅读
乙型肝炎疫苗的接种部位是产生抗体应答的重要因素。有资料证明,当抗-HBs滴度>10IU/l时才有保护效果。但按厂商建议的疫苗接种程序,有68～93%的接种者的抗体滴度达不到该水平。这主要取决于接种途径、疫苗的来源及接种者的年龄和性别。作者用法国巴斯德研究所制备的乙型肝炎疫苗进行了接种观察。在肩胛上区皮下接种3针疫苗,结果有21%的接种者抗体滴度在保护值之下(<10IU/l),其中男性占38%(54/142),女性占17%(103/602)。作者又从这一组人群中随机抽取85名抗体滴度<10IU/l者,再分别经三角肌肌肉接种或肩胛上区皮下接种疫苗。第4针加强免疫后,仍有41%的人未测到抗-HBs,肌肉接种和皮下接
Vaccination site of hepatitis B vaccine is an important factor to produce antibody response. Data have proved that when the anti-HBs titer> 10IU / l have protective effect. However, according to the manufacturer’s recommended vaccination program, 68-93% of vaccinated individuals did not reach this level of antibody titer. This depends on the route of administration, the source of the vaccine and the age and sex of the vaccinee. The authors vaccinated hepatitis B vaccine prepared by the Institut Pasteur in France. Vaccination of the 3-dose vaccine in the suprascapular area led to antibody titer below 21% (<10 IU / l) in 38% of males (54/142) and 17% of women (103% 602). The authors again from this group of 85 randomly selected patients with antibody titers <10IU / l, respectively, after the deltoid muscle or scapular area subcutaneously vaccinated. After the fourth booster immunization, 41% still did not detect anti-HBs, muscle inoculation and subcutaneous